Multifunctional exosome-based hydrocolloid gel for post-shave skincare
AB2003 exosome-based hydrocolloid gel enhances wound healing, reduces inflammation, and promotes skin rejuvenation post-shave. Utilizing advanced exosome technology, it targets anti-aging, hydration, and protection pathways, making it a pioneering solution in skincare.
Overview
The multifunctional exosome-based hydrocolloid gel leverages the unique properties of AB2003 exosomes, derived from human trophoblast stem cell cultures, to provide a breakthrough in post-shave skincare. This innovative formulation is designed to enhance wound healing, reduce inflammation, and rejuvenate skin by targeting key proteins associated with aging and cellular senescence. The gel offers a comprehensive skincare solution by improving hydration, collagen production, and elasticity, while also offering protection against UV damage and promoting DNA repair. This makes it an ideal candidate for those seeking advanced post-shave skincare benefits.
Technical specifications
AB2003 exosomes have been shown to modulate pathways involved in cellular aging and inflammation, with proteomic analysis confirming their ability to restore downregulated proteins in senescent cells. The hydrocolloid gel uses Poloxamer 407 (Pluronic® F-127), known for its unique gelation properties at body temperature, to ensure the stability and functionality of exosomes. The formulation will undergo biophysical characterization and exosome release studies, with tests for cytotoxicity, wound healing, collagen deposition, and angiogenic ability. Additional studies will focus on overcoming UV-induced cytotoxicity and oxidative stress using human keratinocytes, as well as evaluating water retention and skin barrier functions.
Technology readiness level
This technology is currently at Technology Readiness Level 3, with ongoing in vivo studies planned to further validate its efficacy and safety. The formulation will be subjected to rigorous testing to establish its feasibility as a post-shave skincare solution, ensuring it meets industry standards and consumer expectations.
About Accelerated Biosciences Corp.
Accelerated Biosciences Corp. is a biotechnology company that commercializes human trophoblast stem cell (hTSC) technology for applications in regenerative medicine. The company’s core platform utilizes hTSCs, which are ethically sourced pluripotent stem cells isolated from non-viable ectopic pregnancy tissue. These cells are characterized by their natural immune-privileged status, genetic stability, and high scalability. Beyond its proprietary hTSC lines, the company provides genetically engineered platforms, including GEMS (Genetically Engineered Modules) and CHO-GEMS, which enable precision genetic editing for uses such as complex protein production, viral vector manufacturing, and cell therapy development. The company operates by licensing its patented technology, protocols, and GMP-grade starting materials to partners in the biopharma and academic sectors, aiming to streamline the development of novel therapeutic products.
By offering a robust intellectual property portfolio and standardized manufacturing processes, Accelerated Biosciences helps partners reduce development costs and accelerate the transition from research to commercialization. Their hTSC-derived materials, including induced pluripotent stem cells (iPSCs) and exosomes, support a wide range of therapeutic modalities, including immunotherapy, organ repair, and longevity research. Through strategic collaborations with leading research institutions and contract manufacturing organizations, the company is building an ecosystem designed to address critical challenges in healthcare. The firm provides both research-use-only and clinical-grade materials, supporting a broad spectrum of innovation from early-stage discovery to advanced therapeutic design and production.
delivered to your inbox.